Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells

被引：0
|
作者：
Xiaomin Feng
Hao Liu
Zhijie Zhang
Yixue Gu
Huisi Qiu
Zhimin He
机构：
[1] Cancer Hospital and Cancer Research Institute,
[2] Guangzhou Medical University,undefined
[3] Guangzhou,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 36卷
关键词：
Annexin A2; Cisplatin resistance; Apoptosis; p53; JNK; C-Jun; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells
    Miyake, Naomi
    Chikumi, Hiroki
    Takata, Miyako
    Nakamoto, Masaki
    Igishi, Tadashi
    Shimizu, Eiji
    ONCOLOGY REPORTS, 2012, 28 (03) : 848 - 854
  • [42] miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1
    Zhang, Haifeng
    Hu, Baoli
    Wang, Zuopei
    Zhang, Feng
    Wei, Haitao
    Li, Li
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (05) : 973 - 984
  • [43] miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1
    Haifeng Zhang
    Baoli Hu
    Zuopei Wang
    Feng Zhang
    Haitao Wei
    Li Li
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 973 - 984
  • [44] Elevated N-Glycosylation Contributes to the Cisplatin Resistance of Non-Small Cell Lung Cancer Cells Revealed by Membrane Proteomic and Glycoproteomic Analysis
    Zeng, Wenjuan
    Zheng, Shanshan
    Mao, Yonghong
    Wang, Shisheng
    Zhong, Yi
    Cao, Wei
    Su, Tao
    Gong, Meng
    Cheng, Jingqiu
    Zhang, Yong
    Yang, Hao
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [45] Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer
    Shi, Liang
    Li, Yiming
    Yu, Tingting
    Wang, Zeng
    Zhou, Chenxi
    Xing, Wenxiu
    Xu, Gaoqi
    Tong, BingLei
    Zheng, Yingchao
    Zhou, Jie
    Huang, Ping
    MEDICAL SCIENCE MONITOR, 2018, 24 : 8655 - 8668
  • [46] Activation of AKT/ERK confers non-small cell lung cancer cells resistance to vinorelbine
    Fan, Da-Ping
    Zhang, Yi-Mei
    Hu, Xiao-Chen
    Li, Jing-Jing
    Zhang, Wei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (01): : 134 - 143
  • [47] Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer
    Gregorc, V
    Ludovini, V
    Pistola, L
    Darwish, S
    Floriani, I
    Bellezza, G
    Sidoni, A
    Cavaliere, A
    Scheibel, M
    De Angelis, V
    Bucciarelli, E
    Tonato, M
    LUNG CANCER, 2003, 39 (01) : 41 - 48
  • [48] CNPY2 enhances resistance to apoptosis induced by cisplatin via activation of NF-κB pathway in human non-small cell lung cancer
    Dou, Yu
    Yu, Qin
    Lei, Jun-qiang
    Guo, Shun-lin
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 103 : 1658 - 1663
  • [49] p53 mutations in non-small cell lung cancer in Poland
    Niklinski, J
    Rusin, M
    Chyczewski, L
    Sipowicz, M
    Shiao, YE
    Niklinska, WE
    Laudanski, J
    Furman, M
    Chorazy, M
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S30 - S30
  • [50] P53 as a prognostic indicator in non-small cell lung cancer
    Tsobanidou, Ch.
    Papageorgiou, A.
    Anestakis, D.
    Paraskevopoulos, P.
    Angel, J.
    Toliou, Th.
    LUNG CANCER, 2006, 52 : S39 - S39
12345